Management of Stage I Testicular Cancer

Jerusha Padayachee; Roderick Clark; Padraig Warde; Robert J. Hamilton


Curr Opin Urol. 2022;32(1):17-23. 

In This Article


There has been a recent increase in survivorship data after treatment for testicular cancer. Increasingly, research is focusing on the short-term and long-term physical and psychosocial issues that testicular cancer survivor's face. This is especially relevant for individuals with CSI GCTs, as they are eligible for active surveillance, chemotherapy, radiotherapy or RPLND. Kerns et al.[54] recently reported on adverse health outcomes following cisplatin chemotherapy in 1815 survivors of testicular cancer. Note was made of higher rates of peripheral neuropathy, hearing loss and pain, which in turn were associated with greater unemployment amongst treated patients. In addition, potential late CVD following testicular cancer treatments is well recognized. In a recent comprehensive review by Lavi et al.[55] patients treated for NSGCT had increased CVD-related death compared with the general population (hazard ratio 2.03). Taken together, these highlight that better uptake of survivorship clinics are warranted to assess, monitor and minimize risks of treatment-related sequelae.